WaferGen's MyDesign Open Platform Facilitates Rapid Development of a Proprietary Prostate Cancer Diagnostic Panel in the Lab of

     WaferGen's MyDesign Open Platform Facilitates Rapid Development of a
Proprietary Prostate Cancer Diagnostic Panel in the Lab of Dr. Arul Chinnaiyan
                 at the University of Michigan Cancer Center

Platform's Flexibility Key to a Successful Testing of Long Non-Coding RNA
(lncRNA) Markers via High-Throughput Real-Time qPCR

PR Newswire

FREMONT, Calif., Jan. 28, 2013

FREMONT, Calif., Jan. 28, 2013 /PRNewswire/ -- WaferGen Bio-systems, Inc.
(OTCBB: WGBS) today announced the results of a successful study of lncRNA
markers associated with prostate cancer in the lab of Dr. Arul Chinnaiyan at
the University of Michigan Cancer Center. The results can be viewed in white
paper form at:


Under an existing agreement, WaferGen holds a license to this and other
lncRNA-based research reagents developed by Dr. Chinnaiyan's lab.

Dr. Arul Chinnaiyan, the S.P. Hicks Professor of Pathology and Urology at
University of Michigan and the lead author of the study stated: "The WaferGen
SmartChip system is an ideal technology to validate the expression of novel
lncRNAs nominated by RNA-seq in a highly parallel fashion. It allows us to
test multiple primer sets for qPCR very efficiently and cost-effectively,
because of the platform's flexibility. We were able to vary experiment
formats in terms of number of analytes and samples that were driven by each
experiment's design. Furthermore, we could change content rapidly by
dispensing assays in our own lab using WaferGen's multi-sample
nano-dispenser. We intend to validate a number of lncRNA panels for a variety
of common solid tumors, and hope to translate the findings into clinical
practice as proprietary diagnostics." 

The latest marker validation study further underscores the now dual-role of
WaferGen's SmartChip system in enhancing and augmenting experiments using
Next-Gen sequencing (NGS). As recently announced, the system has shown
promise upstream from NGS in target amplification, while downstream from NGS
it can play a valuable role in target validation. This capability will enable
a lab to prepare samples for targeted resequencing, and to confirm the NGS
results via high-throughput nano-qPCR. Both applications leverage SmartChip's
best-in-class flexibility, high levels of sensitivity and dynamic range
without the need for pre-amplification, and a very low cost per reaction.

About WaferGen and the SmartChip Real-Time PCR System

WaferGen Bio-systems, Inc. is an innovative life science company that offers
the SmartChip Real-Time PCR System—a next-generation genetic analysis platform
for profiling and validating molecular biomarkers. It provides a range of
high-throughput capabilities including microRNA and mRNA gene expression
profiling as well as single nucleotide polymorphism (SNP) genotyping. 

For additional information, please see http://www.wafergen.com

Forward Looking Statements

This press release contains certain "forward-looking statements". Such
statements include statements relating to the expected benefits to the Company
of using nano-qPCR technology for target enrichment sample preparation prior
to targeted resequencing on Next-Gen platforms and other statements relating
to future events that are not historical facts, including statements which may
be preceded by the words "will," "believes" or similar words. Forward-looking
statements are not guarantees of future performance, are based on certain
assumptions and are subject to various known and unknown risks and
uncertainties, many of which are beyond the control of the Company. Actual
results may differ materially from the expectations contained in the
forward-looking statements. More detailed information about the Company and
the risk factors that may affect the realization of forward-looking statements
is set forth in the Company's filings with the Securities and Exchange
Commission, including the Company's Annual Report on Form 10-K for the year
ended December 31, 2011. Security holders are urged to read these documents
free of charge on the SEC's web site at www.sec.gov. The Company does not
undertake to publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.

WaferGen Contact:
John Harland

SOURCE WaferGen Bio-systems, Inc.

Website: http://www.wafergen.com
Press spacebar to pause and continue. Press esc to stop.